Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 324

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 324
---
,183 90,155 Intangible asset amortization7,317 7,317 Stock-based compensation expense1,692,267 1,474,758 Net accretion of discount on marketable securities— (161,639)Change in assets and liabilities:  (Increase) decrease in:  Prepaid expenses and other current assets1,102,391 248,895 Other assets548,902 30,000 Increase (decrease) in:  Accounts payable(687,871)117,393 Accrued expenses(1,608,683)(2,762,534)Lease liabilities(80,139)(81,703)Other liabilities(177,134)(236,136)Net cash used in operating activities(14,080,638)(15,491,114)Cash flows from investing activities:  Purchases of property and equipment(8,945)(37,478)Maturities of marketable securities— 21,430,000 Net cash (used in) provided by investing activities(8,945)21,392,522 Cash flows from financing activities:  Proceeds from exercise of stock options— 732,458 Proceeds from issuance of common stock under employee stock purchase plan133,892 247,465 Proceeds from issuance of common stock under at-the-market offering, net of offering expenses13,676,667 — Net cash provided by financing activities13,810,559 979,923 Net (decrease) increase in cash and cash equivalents(279,024)6,881,331 Cash and cash equivalents at beginning of period36,144,720 59,405,817 Cash and cash equivalents at end of period$35,865,696 $66,287,148 Supplemental disclosures of noncash information:  Deferred offering costs included in accounts payable and accrued expenses$64,015 $214,736 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

10

IMMUNEERING CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Organization and Nature of Business

Immuneering Corporation, a Delaware corporation (“Immuneering” or the “Company”), was incorporated in 2008. Immuneering is a clinical-stage oncology company seeking to develop medicines for broad populations of cancer